Your browser doesn't support javascript.
Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics.
Meziyerh, Soufian; Zwart, Tom C; van Etten, Ronald W; Janson, Jeroen A; van Gelder, Teun; Alwayn, Ian P J; de Fijter, Johan W; Reinders, Marlies E J; Moes, Dirk J A R; de Vries, Aiko P J.
  • Meziyerh S; Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
  • Zwart TC; LUMC Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
  • van Etten RW; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
  • Janson JA; Department of Internal Medicine, Division of Nephrology, Amphia Hospital, Breda, The Netherlands.
  • van Gelder T; Department of Intensive Care, Leiden University Medical Center, Leiden, The Netherlands.
  • Alwayn IPJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
  • de Fijter JW; LUMC Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
  • Reinders MEJ; Department of Surgery, Division of Transplantation Surgery, Leiden University Medical Center, Leiden, The Netherlands.
  • Moes DJAR; Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
  • de Vries APJ; LUMC Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
Am J Transplant ; 20(7): 1896-1901, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: covidwho-125541
ABSTRACT
The current coronavirus disease 2019 (COVID-19) pandemic requires extra attention for immunocompromised patients, including solid organ transplant recipients. We report on a case of a 35-year-old renal transplant recipient who suffered from a severe COVID-19 pneumonia. The clinical course was complicated by extreme overexposure to the mammalian target of rapamycin inhibitor everolimus, following coadministration of chloroquine and lopinavir/ritonavir therapy. The case is illustrative for dilemmas that transplant professionals may face in the absence of evidence-based COVID-19 therapy and concurrent pressure for exploration of experimental pharmacological treatment options. However, the risk-benefit balance of experimental or off-label therapy may be weighed differently in organ transplant recipients than in otherwise healthy COVID-19 patients, owing to their immunocompromised status and potential drug interactions with immunosuppressive therapy. With this case report, we aimed to achieve increased awareness and improved management of drug-drug interactions associated with the various treatment options for COVID-19 in renal transplant patients.
Asunto(s)
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Neumonía Viral / Trasplante de Riñón / Infecciones por Coronavirus / Receptores de Trasplantes / Everolimus / Fallo Renal Crónico Tipo de estudio: Reporte de caso / Estudio pronóstico Tópicos: Covid persistente Límite: Adulto / Humanos / Masculino País/Región como asunto: Europa Idioma: Inglés Revista: Am J Transplant Asunto de la revista: Trasplante Año: 2020 Tipo del documento: Artículo País de afiliación: Ajt.15943

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Neumonía Viral / Trasplante de Riñón / Infecciones por Coronavirus / Receptores de Trasplantes / Everolimus / Fallo Renal Crónico Tipo de estudio: Reporte de caso / Estudio pronóstico Tópicos: Covid persistente Límite: Adulto / Humanos / Masculino País/Región como asunto: Europa Idioma: Inglés Revista: Am J Transplant Asunto de la revista: Trasplante Año: 2020 Tipo del documento: Artículo País de afiliación: Ajt.15943